XmAb-968

N/A

Report date: 2026/03/19 17:18:42

Base Information

Drug NameXmAb-968

Drug Alias NameXmAb968

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD38Anti-CD3

TargetsLymphocyte differentiation antigen CD38T cell surface glycoprotein CD3

Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Promyelocytic, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesXencor Inc

China Registration ClassN/A

Develop Information

Active CompaniesXencor Inc

Inactive CompaniesN/A

Active IndicationsHematologic NeoplasmsLeukemia, Promyelocytic, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A